The pneumococcal virulence factors include capsule, PspA, PspC, and Ply. Cytometric analysis demonstrated that the greatest levels of C3 deposition were on a ⌬ply PspA ؊ PspC ؊ mutant. Also, Ply, PspA, and PspC expression resulted in C3 degradation in vitro and in vivo. Finally, blood clearance assays demonstrated that there was enhanced clearance of ⌬ply PspA ؊ PspC ؊ pneumococci compared to the clearance of nonencapsulated pneumococci.
Streptococcus pneumoniae possesses virulence factors that function in evasion of complement (3, (27) (28) (29) . The capsular polysaccharide (CPS) is considered a key factor in complement resistance (13, 21) , and the interaction of pneumococci with complement varies according to the CPS type (1, 15, 19) . Ply can activate the classical pathway, diverting complement activation (26, 29) . Pneumococcal surface protein A (PspA) can also interfere with complement deposition, blocking recruitment of alternative pathway (AP) proteins (4, 24) . Pneumococcal surface protein C (PspC; also called CbpA and SpsA) interacts with factor H (7, 22) . Factor H regulates the AP by serving as a cofactor during factor I-mediated cleavage of C3b to iC3b (10, 11, 16, 25) . Studies have demonstrated that more C3b is deposited on nonencapsulated pneumococci (30) and on PspA Ϫ or Ply Ϫ strains (24, 31) . PspC mutants are less able to inhibit AP activation (17) and have reduced virulence (9) . We investigated C3 deposition, complement inactivation, and blood clearance of pneumococci in the absence of Ply, PspA, and PspC.
Pneumococcal strains, growth conditions, and CPS determination. The pneumococci used are listed in Table 1 and  include R36A, D39, and isogenic mutants of D39. LM91,  TRE108 , and TRE121 are insertion-duplication mutants, and ⌬PLY2 and ⌬PAC (generated for this study by deleting ply of TRE121) were generated by allelic replacement (29) . Bacteria were grown to mid-log phase as described previously (22) . When necessary, erythromycin (0.5 g/ml), tetracycline (15 g/ml), and trimethoprim (50 g/ml) were added to media.
To investigate the combined role of Ply, PspA, and PspC in C3 deposition, we generated ⌬PAC. Experiments with ⌬PAC were repeated using independent clones from different transformations to ensure that the results were not due to inadvertent mutations. Growth curves demonstrated that growth of D39 and growth of ⌬PAC were similar (not shown). The amount of CPS was determined by an enzyme-linked immunosorbent assay as previously described (8) , using an anti-CPS type 2 monoclonal antibody, monoclonal antibody 2G1 (provided by M. H. Nahm). D39 and mutants of this strain had similar levels of CPS. The endpoint titers for D39, ⌬PAC, and TRE121 were 1,160 Ϯ 655, 1,350 Ϯ 540, and 1,340 Ϯ 530 (means Ϯ standard errors of the means), respectively; these values were significantly different (P ϭ 0.03) from the value for R36A (Յ10). CPS of pneumococci was also detected by flow cytometry (fluorescence-activated cell sorting; FACScan cytometer; Becton Dickinson) as described previously (22) using monoclonal antibody 2G1, which demonstrated that CPS was present on viable D39 and ⌬PAC (not shown). The capsules of D39 and ⌬PAC were visualized following staining with Alcian Blue 8GX (Sigma) by transmission electron microscopy as described previously (14) (Fig. 1) .
C3 deposition on the pneumococcal surface. C3 deposition assays were performed as described previously (24) , except that pneumococci (10 5 CFU/ml) were incubated with normal human serum (NHS) (CompTech) as a complement source. C3 was then detected using goat anti-human C3-biotinylated (1:100 dilution) (CompTech) and strepavidin-conjugated Alexa Fluor 488 (Molecular Probes). Fluorescence-activated cell sorting was used to calculate the percentage of C3-positive bacteria and mean fluorescence intensities (MFI). The results demonstrated that the percentages of ⌬PAC, TRE121, and single mutants that were C3 positive were consistently greater than the percentage of D39 that was C3 positive ( Fig. 2A) . The MFI of D39, LM91, TRE108, ⌬PLY2, TRE121, R36A, and ⌬PAC were 7.8 Ϯ 4, 57.7 Ϯ 7, 71.3 Ϯ 8, 75.7 Ϯ 5, 102 Ϯ 16.1, With the exception of ⌬PAC, the mutant strains have been described previously. LM91 has been described by McDaniel et al. (20) , TRE108 has been described by Brooks-Walter et al. (5) , ⌬PLY2 has been described by Thornton and McDaniel (29) , and TRE121 has been described by Balachandran et al. (2) . R36A is a derivative of D39, and all mutant strains are isogenic mutants of D39.
138 Ϯ 39.5, and 468.4 Ϯ 50, respectively. Histograms demonstrated that more C3 was present on ⌬PAC (Fig. 2B) . These data support the findings of other studies that demonstrated the synergistic roles of Ply and PspA in complement inhibition (31) and suggest that in the absence of virulence proteins, pneumococci are more vulnerable to complement than a nonencapsulated strain is.
In vitro and in vivo C3 processing by pneumococci expressing Ply, PspA, and PspC. We first investigated the role of Ply, PspA, and PspC in complement inactivation using in vitro C3 degradation assays. Western analysis was performed as described previously to detect iC3b (6, 23) , except that pneumococci (10 5 CFU/ml) were incubated with 20% NHS for 30 min at 37°C. C3 fragments in supernatants were analyzed by Western blotting using an anti-human iC3b monoclonal antibody (Quidel). This antibody detects generation of iC3b, which serves as an indicator of AP activity. The remaining incubation procedures were performed as described previously (6, 23) . Degradation of C3b to iC3b resulted in the appearance of 75-and 40-kDa fragments. With D39 and R36A we detected degradation of human C3b (109 kDa) to iC3b, as indicated by the appearance of 75-and 40-kDa bands. TRE121 exhibited some ability to degrade C3b, whereas ⌬PAC was unable to cleave C3b as efficiently as the other strains (Fig. 3A) . These results To demonstrate C3 processing in vivo, we used previously described methods (12) , except that naïve CBA/N mice (Jackson Laboratories) were challenged intravenously with 10 8 CFU of D39, R36A, or ⌬PAC suspended in 0.2 ml of lactated Ringer's solution. Blood samples were collected from mice by retroorbital bleeding at 5, 10, 20, and 30 min postinfection. Serum was collected and diluted 1:25 with 2ϫ sodium dodecyl sulfate loading buffer, and 20 l of each sample was used in a Western analysis as described previously (12) with polyclonal goat antimouse C3 (Immunology Consultants Laboratory). Figure 3B shows the C3, C3b, and inactivated fragments in mouse serum at 5, 10, 20, and 30 min after infection with different strains. C3 (bands at approximately 120 to 170 kDa) was detected in naïve mouse serum and in serum 5 min after infection with ⌬PAC, R36A, and D39. iC3b was more evident in serum collected after challenge with D39 or R36A, as indicated by the presence of bands at approximately 70 and 43 kDa at 10 min. This pattern of C3 inactivation was not as evident after infection with ⌬PAC. These observations supported the results of the in vitro C3 assays and further suggest that expression of Ply, PspA, and PspC, independent of the CPS, accelerates C3 inactivation that could enhance pneumococcal survival.
Pneumococcal clearance during infection. Clearance assays were performed as described previously (2, 18, 23) , and groups of five CBA/N mice per challenge strain were infected intravenously with 2 ϫ 10 4 CFU of pneumococci (Table 1 ). Blood was collected at zero time, 10 and 20 min, and 24 h. Pneumococci in blood were enumerated by plating serial dilutions on blood agar. Three independent experiments were performed, and all animal experiments were conducted by following the University of Mississippi Medical Center IACUC guidelines. We also monitored the mortality of mice for up to 21 days. Data from clearance assays demonstrated that mice challenged with D39 had the highest number of pneumococci in their blood at 24 h (Fig. 4) . A significant reduction in the number of nonencapsulated pneumococci in the bloodstream occurred after 20 min, whereas the numbers of the combination mutants were significantly reduced by 10 min and at 20 min (Fig. 4) . This indicates that in the absence of Ply, PspA, and PspC the type 2 CPS cannot effectively evade early innate responses and suggests that the rapid clearance of TRE121 and ⌬PAC could be due to their inability to successfully evade complement deposition.
Together, our results obtained using ⌬PAC extend previous observations demonstrating that PspC has an additive role in complement deposition and emphasize the importance of Ply, PspA, and PspC in the establishment of pneumococcal disease. Since other workers have used C3-deficient mice to demonstrate that virulence can be restored in PspA, PspA-Ply, and PspC mutants (13, 31) , it would be of value to use complementdeficient mice to investigate complement-independent virulence mechanisms employed by ⌬PAC. The results of such studies using Ply-, PspA-, and PspC-deficient mutants belonging to different serotypes may identify common complementdependent and -independent pneumococcal virulence mechanisms.
We are grateful to Moon H. Nahm (supported by grant AI30021) for providing the anticapsular antibody and to Glenn Hoskins for preparing the electron micrographs. We also thank Edwin Swiatlo for his critical reading of the manuscript. Finally, we appreciate the technical assistance of Justin Thornton and Chinwendu Onwubiko. Three independent experiments using groups of five mice per challenge strain were performed, and the mortality of mice was monitored for 21 days after infection. Mice challenged with D39 succumbed to infection by 36 h, and mice challenged with pneumococci lacking only one of the virulence proteins succumbed to infection between 48 and 72 h after infection. The values are the numbers of pneumococci in blood (log CFU/ml; mean Ϯ the standard error of the mean), and Student's t test was used to compare pneumococcal clearance data. A P value of Ͻ0.05 was considered significant. 
